BioSpace News Archive

StageZero Life Sciences today announced its third quarter financial results for the three and nine months ended September 30, 2023, and will provide an update on its business operations.

Evaxion Biotech A/S presents for the first time its AI model designed to predict patient responses to cancer immunotherapy at the Biomarkers & Precision Oncology Europe conference in Berlin, Germany.

MBX Biosciences, Inc. today announced that Kent Hawryluk, President and Chief Executive Officer, will present at the Piper Sandler 35th Annual Healthcare Conference on Wednesday, November 29th , 2023, at 9:10 a.m. Eastern Time and will host 1-on-1 investor meetings.

PepGen Inc. today announced the appointment of Howard Mayer, M.D. to the PepGen Board of Directors, effective November 15, 2023.

eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced a poster presentation of new clinical data from dose escalation and Phase 2 expansion cohorts of a Phase 1/2 clinical study of zotatifin in patients with estrogen receptor positive (ER+) metastatic breast cancer (mBC) at the San Antonio Breast Cancer Symposium 2023 Annual Meeting.

Grifols (MCE: GRF, MCE: GRF.P NASDAQ: GRFS) today announced that it has completed Cohort 1 of its Phase 1/2 study (NCT04722887) evaluating Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% (Alpha-1 15%), a subcutaneous (SC) alpha1 antitrypsin (AAT) treatment being compared to Liquid Alpha1-Proteinase Inhibitor (Human) intravenous (IV).

Ascendis Pharma A/S (Nasdaq: ASND) today announced that it has resubmitted its New Drug Application (NDA) for TransCon PTH (palopegteriparatide) for the treatment of adults with hypoparathyroidism to the U.S. Food & Drug Administration (FDA).

Enhanced External Counterpulsation (EECP®), a non-invasive treatment that increases blood flow, is a promising solution for patients with Angina with No Obstructive Coronary Arteries (ANOCA). Findings were presented at the American Heart Association 2023 Scientific Sessions on Nov 11, 2023, with a concurrent publication in the American Journal of Cardiology.

Cytovale® announced it has raised $84 million in Series C funding led by Norwest Venture Partners with participation by additional new investors Sands Capital and Global Health Investment Corporation.

AtriCure, Inc. today announced that the company will be participating in the upcoming Piper Sandler 35th Annual Healthcare Conference.